Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                CTP Newsroom

CTP Newsroom

                        Feature Stories Home
          Tobacco Products
          CTP Newsroom
          FDA Denies Marketing of 250+ Flavored and Tobacco-Flavored E-LiquidsCTP Newsroom FDA Denies Marketing of 250+ Flavored and Tobacco-Flavored E-Liquids
  
  					Multidisciplinary Scientific Review Finds Products Do Not Meet the Necessary Public Health Standard
	
    Share
    Post
    Linkedin

    Email
    PrintToday, FDA issued marketing denial orders to the firm Mothers Milk WTA for more than 250 flavored and tobacco-flavored e-liquids. After completing initial acceptance review and subsequently proceeding to and completing a substantive scientific review of the company’s premarket tobacco product applications (PMTAs), FDA determined that the applications lacked sufficient evidence to show the products are appropriate for the protection of public health. For example, among other things, the applications did not provide sufficient evidence to show comparative health risk data relative to other tobacco products on the U.S. market, information assessing the abuse liability of the new products, or that the new products could be manufactured consistently.

“One of our most important responsibilities is to ensure new tobacco products undergo scientifically rigorous premarket review,” says Matthew Farrelly, Ph.D., Director of the Office of Science within FDA’s Center for Tobacco Products. “We remain committed to evaluating these applications based on a public health standard that considers the risks and benefits of the tobacco product to the population as a whole.”

There are several phases in the PMTA review process. If an application does not meet the necessary requirements for a given phase, FDA may issue a refuse to accept letter or refuse to file letter and not move the application forward in the process. During the final substantive review phase, FDA evaluates the scientific information and data in applications to determine if marketing of the new products meet the requirements of the appropriate for the protection of public health standard set forth by Congress for new tobacco products in the 2009 Family Smoking Prevention and Tobacco Control Act.

Following FDA’s rigorous scientific review, tobacco products that receive a marketing denial order may not be offered for sale, distributed, or marketed in the U.S. Additionally, such products may not be introduced or delivered for introduction into interstate commerce, and if the product is already on the market, the product must be removed from the market. Manufacturers, distributors, and retailers who do sell, distribute, or market these products are violating the law and are at risk of enforcement action.

Today’s action is further evidence of FDA’s progress toward making sure that all new tobacco products have undergone science-based review and received marketing authorization by FDA before they can be legally marketed.

“We’ve made considerable progress in reviewing the unprecedented volume of applications that have been submitted—completing review of 99% of submissions to date,” says Brian King, Ph.D., M.P.H., Director of FDA’s Center for Tobacco Products. “The remaining reviews are going to be completed, but it’s critical that we take the appropriate time needed by the multidisciplinary teams involved to ensure that the reviews are both scientifically and legally defensible.”

To date, the agency has received premarket tobacco applications for more than 26 million deemed products, the majority of which are e-cigarettes. The agency has made determinations on 99% of these applications. This includes more than 1 million applications for non-tobacco nicotine products, including those containing synthetic nicotine, after Congress clarified FDA’s authority to regulate these products in April 2022. Further, FDA has authorized 23 tobacco-flavored e-cigarette products and devices, which are the only e-cigarettes that currently may be lawfully sold or distributed in the U.S. FDA has also denied marketing applications for millions of products that did not meet the requirements in the law.

Find more information about FDA’s tobacco product authorizations and marketing denial orders on FDA’s website.

                                                                                  Content current as of:
      05/18/2023
              
              
Regulated Product(s)
		 TobaccoCTP Newsroom

          
                        Feature Stories
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop